• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2.44 SEK

-3.94 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.94 %
-22.95 %
-61.47 %
-52.03 %
-58.26 %
-59.48 %
-21.74 %
-
-59.61 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
162.84M SEK
Turnover
1.74M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8
2026

Interim report Q2'26

27.11
2026

Interim report Q3'26

16.2
2027

Annual report '26

Regulatory press releaseyesterday

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics
Regulatory press release6/3/2026, 3:01 PM

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics
Regulatory press release6/1/2026, 3:46 PM

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/25/2026, 7:10 AM

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Press release5/19/2026, 8:10 AM

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Press release5/13/2026, 1:57 PM

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Regulatory press release5/11/2026, 12:16 PM

Elicera Therapeutics: Elicera publishes information document regarding the rights issue

Elicera Therapeutics
Press release4/21/2026, 6:53 PM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement - Correction

Elicera Therapeutics
Press release4/21/2026, 9:15 AM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement

Elicera Therapeutics
Regulatory press release4/21/2026, 6:31 AM

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

Elicera Therapeutics
Regulatory press release4/21/2026, 6:01 AM

Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026

Elicera Therapeutics
Press release3/20/2026, 7:53 AM

Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu

Elicera Therapeutics
Press release3/13/2026, 5:48 AM

DNB Carnegie Access: Elicera Therapeutics: Focused on the future of immuno-oncology

Elicera Therapeutics
Press release3/11/2026, 9:53 AM

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Elicera Therapeutics
Press release3/10/2026, 8:41 AM

Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Elicera Therapeutics
Regulatory press release3/6/2026, 7:30 AM

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Elicera Therapeutics
Press release2/27/2026, 7:30 AM

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Elicera Therapeutics
Press release2/18/2026, 12:57 PM

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Elicera Therapeutics
Regulatory press release2/13/2026, 7:20 AM

Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025

Elicera Therapeutics
Press release2/11/2026, 1:32 PM

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Elicera Therapeutics